Showing 21 - 40 results of 196 for search 'app sequence model', query time: 0.10s Refine Results
  1. 21

    Temporal transcriptomic changes in the THY-Tau22 mouse model of tauopathy display cell type- and sex-specific differences by Muhammad Ali, Pierre Garcia, Laetitia P. Lunkes, Alessia Sciortino, Melanie H. Thomas, Tony Heurtaux, Kamil Grzyb, Rashi Halder, Alexander Skupin, Luc Buée, David Blum, Manuel Buttini, Enrico Glaab

    Published 2025-05-01
    “…To validate the most robust findings across distinct mouse models and species, the results were compared with cortical scRNA-seq data from the transgenic hAPP-based Tg2576 mouse model and human AD. …”
    Get full text
    Article
  2. 22

    Long-read RNA-sequencing reveals transcript-specific regulation in human-derived cortical neurons by Jishu Xu, Michaela Hörner, Elena Buena Atienza, Kalaivani Manibarathi, Maike Nagel, Stefan Hauser, Jakob Admard, Nicolas Casadei, Stephan Ossowski, Rebecca Schuele

    Published 2025-07-01
    “…In this study, we employed nanopore long-read RNA sequencing to profile the transcriptomes of three cell types commonly used to model brain disorders, human fibroblasts, induced pluripotent stem cells and stem cell-derived cortical neurons, identifying extensive transcript diversity with 15 072 transcripts in stem cell-derived cortical neurons, 13 048 in fibroblasts and 12 759 in induced pluripotent stem cells. …”
    Get full text
    Article
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28

    Combination of anlotinib with immunotherapy enhanced both anti-angiogenesis and immune response in high-grade serous ovarian cancer by Hongwei Lan, Hui Liu, Helei Hou, Chuantao Zhang, Jingjuan Zhu, Na Zhou, Xiaochun Zhang

    Published 2025-04-01
    “…Peripheral blood mononuclear cell-derived patient-derived xenograft (PBMC-PDX) model was established from drug-resistant recurrent HGSOC patient-derived tumor cells, and single-cell RNA sequencing (scRNA-seq) was conducted to dissect the TME following treatment with anlotinib, anlotinib + aPD-L1 and anlotinib + aPD-1.ResultsClinical analysis revealed a disease control rate (DCR) of 71.43% for anlotinib monotherapy, which improved to 100% when combined with aPD-L1/aPD-1. …”
    Get full text
    Article
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40